These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 36596729

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH, Chen YF, Chen CY, Shih JY, Yu CJ.
    BMC Cancer; 2019 Oct 26; 19(1):1006. PubMed ID: 31655564
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
    Kwok WC, Ho JCM, Tam TCC, Ip MSM, Lam DCL.
    Thorac Cancer; 2022 Jul 26; 13(14):2057-2063. PubMed ID: 35668712
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep 26; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
    Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.
    Cancer Res Treat; 2019 Apr 26; 51(2):502-509. PubMed ID: 29898592
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
    Arrieta O, Catalán R, Guzmán-Vazquez S, Barrón F, Lara-Mejía L, Soto-Molina H, Ramos-Ramírez M, Flores-Estrada D, de la Garza J.
    BMC Cancer; 2020 Sep 01; 20(1):829. PubMed ID: 32873256
    [Abstract] [Full Text] [Related]

  • 16. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
    Huang YH, Hsu KH, Chin CS, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJW, Chang GC.
    Cancer Res Treat; 2022 Apr 01; 54(2):434-444. PubMed ID: 34352999
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
    Chang JW, Huang CY, Fang YF, Chang CF, Yang CT, Kuo CS, Hsu PC, Wu CE.
    Thorac Cancer; 2023 Jan 01; 14(1):12-23. PubMed ID: 36424878
    [Abstract] [Full Text] [Related]

  • 18. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Tamiya M, Tamiya A, Suzuki H, Moriizumi K, Nakahama K, Taniguchi Y, Kunimasa K, Kimura M, Inoue T, Kuhara H, Nishino K, Hirashima T, Atagi S, Imamura F, Kumagai T.
    Anticancer Res; 2019 Jul 01; 39(7):3923-3929. PubMed ID: 31262922
    [Abstract] [Full Text] [Related]

  • 19. Treatment outcomes of non-small cell lung cancers treated with EGFR tyrosine kinase inhibitors: a real-world cohort study.
    Manninen O, Puuniemi L, Iivanainen S, Arffman M, Kaarteenaho R, Koivunen JP.
    Acta Oncol; 2023 Dec 01; 62(12):1854-1861. PubMed ID: 37934101
    [Abstract] [Full Text] [Related]

  • 20. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
    Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Tsuya A, Fukuoka M, Minami H.
    Jpn J Clin Oncol; 2024 Mar 09; 54(3):319-328. PubMed ID: 37997468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.